Microalbuminuria in essential hypertension and diabetes mellitus
- PMID: 8934384
- DOI: 10.1097/00004872-199609002-00017
Microalbuminuria in essential hypertension and diabetes mellitus
Abstract
Definition: Microalbuminuria is defined as abnormally elevated urinary albumin excretion below the level of clinical albuminuria (albustix). This represents a urinary albumin excretion rate of 20-200 micrograms/min, equal to 30-300 mg/24 h. Urinary albumin excretion can vary as much as 40% with natural fluctuations, and so several tests should be done. Inexpensive radioimmunoassay, enzyme-linked immunosorbent assays or immunoturbidimetric assays are now routine in many clinical laboratories.
Prevalence: The prevalence of microalbuminuria in essential hypertension and diabetes is about the same: 25% (range 14-31) and 20% (9-27), respectively.
Mechanisms: Increased transglomerular passage is the major mechanism of microalbuminuria in both the above-mentioned conditions; increased hydraulic glomerular capillary pressure and glomerular lesions probably both contribute. Microalbuminuria is highly predictive of the development of diabetic nephropathy but the predictive power in relation to hypertensive nephropathy remains to be established. However, in both conditions microalbuminuria is associated with an increased risk of retinopathy, left ventricular hypertrophy, fatal and non-fatal cardiovascular disease and all-cause mortality. The following mechanisms have been suggested as a link between microalbuminuria and these findings: endothelial dysfunction, insulin resistance, hyperinsulinemia, dyslipoproteinemia and a procoagulant state.
Effect of antihypertensive treatment: Blood pressure lowering reduces microalbuminuria in essential hypertension and in diabetes mellitus. Long-term studies in diabetes suggest that angiotensin converting enzyme inhibitors postpone, and may even prevent, progression to overt clinical nephropathy in normotensive diabetic patients with persistent microalbuminuria. So far, there have been no long-term comparative trials on the beneficial effects of different antihypertensive drugs in hypertensive patients with microalbuminuria.
Similar articles
-
Microalbuminuria in essential hypertension.J Hum Hypertens. 2002 Mar;16 Suppl 1:S74-7. doi: 10.1038/sj.jhh.1001348. J Hum Hypertens. 2002. PMID: 11986900 Review.
-
Is antihypertensive treatment the same for NIDDM and IDDM patients?Diabetes Res Clin Pract. 1998 Apr;39 Suppl:S43-7. doi: 10.1016/s0168-8227(98)00017-5. Diabetes Res Clin Pract. 1998. PMID: 9649959 Review.
-
The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes.Cardiovasc J S Afr. 2002 Jul-Aug;13(4):194-9. Cardiovasc J S Afr. 2002. PMID: 12389063 Review.
-
Does antihypertensive treatment prevent progression of microalbuminuria to overt proteinuria in insulin-dependent diabetic patients?J Am Soc Nephrol. 1992 Oct;3(4 Suppl):S91-6. doi: 10.1681/ASN.V34s91. J Am Soc Nephrol. 1992. PMID: 1457766 Review.
-
Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.J Hypertens Suppl. 1998 Jan;16(1):S99-101. J Hypertens Suppl. 1998. PMID: 9534107 Review.
Cited by
-
Drug treatment of hypertension complicating diabetes mellitus.Drugs. 1998 Aug;56(2):189-202. doi: 10.2165/00003495-199856020-00003. Drugs. 1998. PMID: 9711444 Review.
-
Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease.Biomedicines. 2023 Jul 7;11(7):1928. doi: 10.3390/biomedicines11071928. Biomedicines. 2023. PMID: 37509567 Free PMC article. Review.
-
Urinary N-acetyl beta glucosaminidase and gamma glutamyl transferase as early markers of diabetic nephropathy.Indian J Clin Biochem. 2006 Sep;21(2):142-8. doi: 10.1007/BF02912930. Indian J Clin Biochem. 2006. PMID: 23105632 Free PMC article.
-
Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD).Life (Basel). 2021 Mar 10;11(3):224. doi: 10.3390/life11030224. Life (Basel). 2021. PMID: 33802211 Free PMC article. Review.
-
Second manifestations of ARTerial disease (SMART) study: rationale and design.Eur J Epidemiol. 1999 Oct;15(9):773-81. doi: 10.1023/a:1007621514757. Eur J Epidemiol. 1999. PMID: 10608355
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials